bepridil has been researched along with flecainide in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (23.81) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Jia, L; Sun, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Somberg, J | 1 |
| Horowitz, LN; Morganroth, J | 1 |
| Touboul, P | 1 |
| Borchard, U; Dietrich, H; Hafner, D; Hirth, C | 1 |
| Somberg, JC | 1 |
| Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T | 2 |
| Blaker, PA; Davies, M; Hall, SM; Kapoor, R; Smith, KJ | 1 |
| Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K | 1 |
| Aonuma, K; Doki, K; Homma, M; Kuga, K; Sekiguchi, Y | 1 |
1 review(s) available for bepridil and flecainide
| Article | Year |
|---|---|
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Disopyramide; Drug Administration Schedule; Encainide; Flecainide; Heart Conduction System; Humans; Imidazoles; Lidocaine; Mexiletine; Moricizine; Myocardial Contraction; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tocainide; Verapamil | 1985 |
2 trial(s) available for bepridil and flecainide
| Article | Year |
|---|---|
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Flecainide; Humans; Lidocaine; Male; Middle Aged | 2003 |
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Bepridil; Drug Therapy, Combination; Electrocardiography; Female; Flecainide; Follow-Up Studies; Humans; Imidazoles; Lidocaine; Male; Middle Aged; Natriuretic Peptide, Brain; Sinoatrial Node; Treatment Outcome | 2008 |
18 other study(ies) available for bepridil and flecainide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Are there unnecessary delays in the development of new cardiac drugs in the United States?
Topics: Amiodarone; Bepridil; Flecainide; Humans; Pyrrolidines; United States; United States Food and Drug Administration | 1986 |
[New class I anti-arrhythmia agents].
Topics: Anti-Arrhythmia Agents; Bepridil; Flecainide; Humans; Imidazoles; Kinetics; Propafenone; Pyrrolidines | 1986 |
Antiarrhythmic and electrophysiological actions of flecainide, bepridil and amiodarone on isolated heart preparations during controlled hypoxia.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Bepridil; Electrophysiology; Flecainide; Guinea Pigs; Heart; In Vitro Techniques; Male; Membrane Potentials; Myocardial Contraction; Oxygen; Papillary Muscles; Piperidines; Pyrrolidines; Time Factors | 1985 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Death, Sudden; Disopyramide; Encainide; Flecainide; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tachycardia; Tocainide; Verapamil | 1984 |
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Electrocardiography; Female; Flecainide; Humans; Lidocaine; Male; Middle Aged; Sodium Channel Blockers; Treatment Outcome | 2003 |
Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration.
Topics: Anesthetics, Local; Animals; Axons; Bepridil; Calcium; Calcium Channel Blockers; Electrophysiology; Flecainide; Lidocaine; Male; Nerve Degeneration; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Rats; Rats, Sprague-Dawley; Sodium; Sodium Channel Blockers; Sodium-Calcium Exchanger; Spinal Nerve Roots | 2003 |
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity.
Topics: Anti-Arrhythmia Agents; Bepridil; Bignoniaceae; Cytochrome P-450 CYP2D6; DNA, Complementary; Female; Flecainide; Genotype; Humans; Male; Microsomes, Liver; Middle Aged; Pharmacogenetics; Tachycardia; Tachycardia, Supraventricular | 2015 |